Advisory Board
Chief Scientific Advisor

Shan Lu, M.D., Ph.D.

Professor of Medicine at the University of Massachusetts Medical School and a pioneer in gene-based vaccines. In the last two decades, Dr. Lu has used the DNA vaccination approach to develop and optimize vaccines against HIV-1, bioterrorism (plague, smallpox, anthrax and botulinum) and emerging pathogens (SARS, seasonal and pandemic influenza), pathogens causing chronic infectious diseases (hepatitis viruses and CMV), and pathogens causing neglected infectious diseases, including diarrhea (cholera and EV71).

Dr. Lu’s research has focused on the design and delivery of immunogens to highly functional antibody responses. His group developed and tested the first polyvalent DNA prime-protein boost HIV vaccine in humans, which elicited robust and balanced T cell and antibody responses, including cross-subtype neutralizing antibodies against HIV-1 of different subtypes. Dr. Lu’s group developed the first panel of rabbit mAbs against HIV-1 along with their X-ray crystal structures including several with broad cross-reactivity and potent binding affinities.

Dr. Lu is a member of the editorial boards of Journal of Virology, Vaccine, Human Vaccines and Immunotherapeutics, and Current Opinion of Virology. He is a deputy editor-in-chief for Emerging Microbes and Infections, which is published by Nature Publishing Group. He is a board member and the immediate past president of International Society for Vaccines (ISV). He is a fellow of American College of Physicians (FACP) and a fellow of ISV (FISV).

Scientific Advisor

Mark I. Greene, M.D., Ph.D., F.R.C.P.

Dr. Greene is the John W. Eckman Professor of Medical Science and Director of Immunobiology and Experimental Pathology Division at University of Pennsylvania. From 1980 to1986, he was an Associate Professor of both Harvard University and Harvard Medical School. In 1986, Dr. Greene joined the University of Pennsylvania and became the head of Immunology Research and Professor of Pathology and Laboratory Medicine.

His groundbreaking work in the functions of human erbB receptor led to the development of Herceptin (Genentech). His research also leads to the development of a proprietary method for the rapid, reliable design of allosteric inhibitors of receptors and enzymes. He has received multiple patents in the area of antibody and mimetic based cancer therapy, as well as in the engineering of antibody complementarity determining regions. He has concentrated on antibody atomic structure and function for the last 30 years.

Dr. Greene\\\'s laboratory developed an approach to target and down-modulate oncoproteins which when expressed were critical for abnormal malignant cell growth. This simple approach developed in the neu system involved developing monoclonal antibodies specific for the ectodomain of pl85. This was the basis for targeted therapy and the approach has led to improved treatment for early and advanced breast cancer.

Dr. Greene has been recognized with many awards for his work, including Allyn Taylor Prize, Adams County Breast Cancer Research Award and the Cotlove Award. In 2011 Dr. Greene was made an honorary fellow of Lincoln College, Oxford University.

Scientific Advisor

Shuying Liu

Shuying Liu is an independent consultant with broad knowledge and experience in the monoclonal antibody (mAb) technology. For over 20 years working at Amgen, she delivered high affinity and high specificity antibodies against over 150 difficult and challenging targets including GPCRs, ion-channels, and transporters in various therapeutic areas including oncology, metabolic diseases, inflammation, and neuroscience. She was the hybridoma group leader before leaving Amgen Inc. in 2015. Subsequently, she was the director of R & D at Gensun Biopharma Inc., a biotech start-up located in California, USA. She was responsible for managing and supervising company-wide research and development operation: antigen design and production; antibody generation, screening, and characterization; hybridoma cloning; functional assay development and optimization; and bi-specific antibody engineering. As one of the most recognized and respected experts in the field, she has advised many academic and industrial clients on mAb generation and related methodologies to enhance the productivity and quality of their mAb programs.